Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable Tumors.

ABSTRACT:

Background

Surgeons are increasingly asked to operate on patients with residual disease after immunotherapy. The safety and utility of lung resection in this setting are unknown.

Methods

We retrospectively reviewed patients who underwent lung resection within 6 months of treatment with checkpoint blockade agents for metastatic or unresectable cancer. Survival was estimated from the first resection using the Kaplan-Meier approach.

Results

Database query identified 19 patients who underwent 22 resections for suspected residual disease with therapeutic intent after immunotherapy between 2012 and 2016. Lung cancer was the most common diagnosis (47%), followed by metastatic melanoma (37%). The most frequently used agents were nivolumab (32%), pembrolizumab (32%), and ipili

SUBMITTER: Bott MJ 

PROVIDER: S-EPMC6357770 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature